The Technical Analyst
eFFECTOR Therapeutics, [EFTR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
eFFECTOR Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-4.49% $1.700
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 6.27 mill |
| EPS: | -16.37 |
| P/E: | -0.100 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 3.69 mill |
| Avg Daily Volume: | 0.379 mill |
| RATING 2024-04-19 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.100 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.100 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.137 - 3.26 ( +/- 91.94%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-19 | Loewy Caroline M | Buy | 2 000 | Stock Option (Right to Buy) |
| 2024-02-19 | Bhatt Elizabeth | Buy | 2 000 | Stock Option (Right to Buy) |
| 2024-02-19 | Ehrlich Christopher B | Buy | 2 000 | Stock Option (Right to Buy) |
| 2024-02-19 | Klencke Barbara | Buy | 2 000 | Stock Option (Right to Buy) |
| 2024-02-19 | Harrington-smith Kristen | Buy | 2 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 45.96 |
| Last 95 transactions |
| Buy: 5 541 401 | Sell: 1 016 887 |
Forecast:
16:00 - $1.720
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.720
Forecast 2: 16:00 - $1.720
Forecast 3: 16:00 - $1.720
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.700 (-4.49% ) |
| Volume | 0.197 mill |
| Avg. Vol. | 0.379 mill |
| % of Avg. Vol | 51.93 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EFTR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $10.40 | N/A | Active |
|---|
EFTR
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-09 08:00:00 - Press Release
Effector Therapeutics To Participate In Upcoming Investor Conference
Solana beach, calif. and redwood city, calif., april 09, 2024 (globe newswire) -- effector therapeutics, inc. (nasdaq: eftr), a leader in the development of selective translation regulator inhibitors (“stris”) for the treatment of cancer, today announced that the company will present at the stifel virtual oncology forum on tuesday, april 16th at 11:30 am et.
2024-04-04 08:30:00 - Press Release
Effector Therapeutics Announces Topline Results Of Phase 2 Kickstart Trial Of Tomivosertib Combined With Pembrolizumab In Non-small Cell Lung Cancer
Solana beach, calif. and redwood city, calif., april 04, 2024 (globe newswire) -- effector therapeutics, inc. (nasdaq: eftr), a leader in the development of selective translation regulator inhibitors (stris) for the treatment of cancer, today announced topline results from the primary analysis of the randomized phase 2 kickstart trial which tested tomivosertib or placebo, each combined with pembrolizumab, as frontline treatment for patients with non-small cell lung cancer (nsclc) with pd-l1 ≥50%. based on 36 events, the hazard ratio for progression free survival (pfs, the primary endpoint of the study) using a stratified cox proportional hazards model was 0.62 (95% confidence intervals 0.3 to 1...
2024-03-25 16:01:00 - Press Release
Effector Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Corporate Update
Topline data from the randomized phase 2b kickstart trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (nsclc) expected in early april 2024
2024-02-05 08:30:00 - Press Release
Effector Therapeutics To Present At Oppenheimer 34th Annual Healthcare Life Sciences Conference
Solana beach, calif. and redwood city, calif., feb. 05, 2024 (globe newswire) -- effector therapeutics, inc. (nasdaq: eftr), a leader in the development of selective translation regulator inhibitors (“stris”) for the treatment of cancer, today announced that steve worland, ph.d., president, and chief executive officer of effector, will present at the oppenheimer 34th annual healthcare life sciences conference on wednesday, february 14th at 10:40 am et.
2024-01-29 16:05:00 - Press Release
Effector Therapeutics Announces Closing Of $15 Million Registered Direct Offering Priced At-the-market Under Nasdaq Rules
Solana beach, calif. and redwood city, calif., jan. 29, 2024 (globe newswire) -- effector therapeutics, inc. (nasdaq: eftr) (the “company”), a leader in the development of selective translation regulator inhibitors (“stris”) for the treatment of cancer, today announced that it has closed its previously announced registered direct offering with a new healthcare focused institutional investor for the purchase and sale of an aggregate of 1,488,834 shares of its common stock (or common stock equivalents in lieu thereof) and short-term warrants to purchase up to an aggregate of 1,488,834 shares of its common stock at an offering price of $10.075 per share of common stock (or common stock equivalent in lieu thereof) and accompanying short-term warrant priced at-the-market under nasdaq rules...
Latest News
2024-04-09 08:00:00 - GlobeNewsWire
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will present at the Stifel Virtual Oncology Forum on Tuesday, April 16th at 11:30 am ET.
2024-04-05 14:01:06 - Zacks Investment Research
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
eFFECTOR Therapeutics (EFTR) plunges on disappointing top-line results from the primary analysis of its mid-stage NSCLC study of tomivosertib, following the abandonment of the developmental program.
2024-02-05 08:30:00 - GlobeNewsWire
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that Steve Worland, Ph.D., president, and chief executive officer of eFFECTOR, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14th at 10:40 am ET.
2024-01-30 10:56:06 - Zacks Investment Research
Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 814.5% in eFFECTOR Therapeutics, Inc. (EFTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2023-11-16 14:12:36 - PennyStocks
3 Top Penny Stocks To Watch Before Next Week
Have you ever thought about diving into penny stocks? These are the stocks that won't break the bank, typically trading for less than $5.
2023-10-24 09:02:45 - PennyStocks
4 Hot Penny Stocks To Watch With Big News This Week
Whether you're trading penny stocks or stocks over $100, the goal is the same. You want to find opportunities as early as possible and capitalize.
2023-10-02 15:07:38 - InvestorPlace
3 Promising Biotech Stocks That Will Make Early Investors Rich
For investment ideas that can potentially lead to life-changing gains, few sectors are as viable as biotech stocks to make you rich. Fundamentally, the biotechnology sector offers potential therapeutic innovations that could change paradigms for patient care.
2023-08-28 11:42:49 - PennyStocks
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
The traditional approach to investing is finding well-established companies, investing in them and waiting years for a return of 50%. But in today's fast-paced stock market, retail traders are finding better ways to use the stock market to capture gains.
2023-08-25 11:06:16 - PennyStocks
7 Best Penny Stocks To Buy Under $1 in 2023: Big Risk, Big Return?
Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typically from smaller companies, offer the tantalizing possibility of significant returns.
2023-08-24 13:10:24 - PennyStocks
Best Penny Stocks To Buy Under $1.25? 3 To Watch Now
Are you looking for the best penny stocks to buy? You're not alone; many traders are showing a renewed interest in this exciting market.